This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation after implantation of 2nd generation drug-eluting stent. The primary end point was a composite of cardiac death, myocardial infarction, stroke, definite or probable thrombosis, and major bleeding. At 12 months follow-up the primary end point rate was 4.5% in those who received 6 months versus 3.7% in those who received 12 months (p = 0.469). The incidence of definite or probable thrombosis when considering separately, there were no differences (0.3% versus 0.4%, P = 0.694).
Conclusion
Treatment with 6 months of dual anti-aggregation was not minor than 12 months in patients who received angioplasty with 2nd generation drug-eluting stents.
3_antonio_colombo
Antonio Colombo
2014-09-16
Original title: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation.